ROSE Diagnostics Achieves Milestone in verifi™ LUNG Test Development

Carlsbad, CA - August 30th 2025

ROSE Diagnostics Inc., is pleased to announce the successful launch of its sample collection study for the verifi™ LUNG Test system under its Clinical Studies Agreement with Scripps Health Network, a leading nonprofit integrated health system in San Diego, CA. The study has already enrolled its first 15 patients at Scripps (50 in total for the study) and collected initial biopsy specimens, providing valuable insights into specimen matrix characteristics and test performance in ROSE Diagnostics’ laboratories.

“These early milestones exceed internal performance targets and validate the feasibility of the verifi™ LUNG Test in real-world clinical workflows and mark an important step toward broader clinical validation,” said Andrew Morris, CEO of ROSE Diagnostics. “Partnering with a world-class institution like Scripps Health Network highlights the clinical value of our system, and the data we’re collecting will be critical for advancing the test toward commercialization, ultimately improving confidence and outcomes for clinicians and patients.”

The verifi™ LUNG Test system addresses a significant need in lung cancer diagnostics by providing real-time, in-suite assessment of specimen adequacy. Early patient enrollment demonstrates both strong clinical interest and the operational feasibility of integrating the system into existing biopsy workflows.

For further inquiries, please contact: info@rose-dx.com.